SSII is a developer of surgical robotic technologies best known for its SSi Mantra system, which supports robotic-assisted cardiac, thoracic, gynecological, urological, and general procedures. As an early-stage medical device company, quarterly revenue can swing sharply depending on the timing of system installations, making each report a key signal on commercial traction. Investors are also watching the company's cash position, its heavy concentration in the Indian market, and its stated plans to enter the United States and European Union. Against that backdrop, this quarter's results carry extra weight because they test whether the company can sustain the rapid top-line growth it posted in recent periods. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the third quarter ended September 30, 2026, SSII reported revenue of $6.33 million, a decline of 50.65% from $12.83 million in the same period last year. The result fell well short of the roughly $15.1 million analysts had projected. System sales contributed about $4.72 million, instruments about $1.04 million, warranty revenue about $0.56 million, and rental income a small remainder.
The company posted a net loss of $5.75 million, compared with a net loss of $3.72 million a year earlier, translating to a basic and diluted loss per share of $0.03, versus the approximately $0.01 loss analysts had anticipated. Gross margin was 49.09%, modestly higher than 48.05% a year ago, while operating expenses rose 14.55% to about $9.16 million, driven in part by research and development spending and stock-based compensation.
For the first nine months of 2026, revenue reached $31.41 million, up 12.39% from $27.95 million, while the net loss widened to $12.03 million from $9.66 million.
Heading into the report, sentiment around SSII had been supported by strong year-over-year growth in earlier quarters and a single-analyst price target well above the stock's recent trading range. The sharp sequential revenue decline and the wide gap versus consensus are likely to challenge that optimism. A top line of $6.33 million versus an estimate near $15.1 million, combined with a deeper-than-expected per-share loss, suggests investors will focus on whether the shortfall reflects lumpy system-installation timing or a more persistent slowdown in demand. The market's read will also hinge on the company's commentary around its installed base, order pipeline, and progress toward geographic diversification beyond India.
The biggest question for SSII following this report is whether the third-quarter revenue decline is a timing issue or an early sign of softer commercial momentum. Because system sales can be uneven from one quarter to the next, investors will look to the company's order activity and installation pipeline for clues about the trajectory of the fourth quarter and beyond.
Geographic concentration remains a key risk. India accounted for about 97% of quarterly revenue and 94% of revenue over the first nine months, which leaves results highly exposed to a single market. Management has signaled plans to enter the United States and European Union, and any concrete regulatory or commercial milestones on that front would be important catalysts to monitor.
Finally, the balance sheet and funding picture warrant attention. The company ended the quarter with cash and cash equivalents of about $8.11 million and restricted cash of about $10.49 million, against a reported accumulated deficit of roughly $67.82 million. With ongoing research and development investment and stock-based compensation pressuring operating results, investors will likely watch cash burn, financing activity, and any updates on the company's ability to fund its expansion plans without further dilution. From what I see, this remains an area to follow closely.
In my view, tools like Tickeron’s AI Screener can help investors quickly compare companies like SSII against peers in the medical device space. I often turn to it when reviewing fundamentals, technical signals, and industry trends to get a clearer picture before forming my own conclusions on quarterly results.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SSII declined for three days, in 126 of 136 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SSII turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The Aroon Indicator for SSII entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSII advanced for three days, in 62 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
SSII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.846) is normal, around the industry mean (4.142). P/E Ratio (0.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.887) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. SSII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SSII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices